Pharma-major  Cipla Ltd on Wednesday collaborated with the Premier Medical Corporation for commercialization of the rapid antigen test kits for COVID-19 in India. The company will commence supply from this week. As per the deal, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be made by Premier Medical Corporation.

"In this collaboration, Cipla will be responsible for the marketing and distribution of the Rapid Antigen Detection Test for the qualitative detection of SARS-CoV-2 antigen that will be manufactured by Premier Medical Corporation Pvt Ltd," Cipla said in a regulatory filing.

The company said it will commence the supply of rapid point-of-care nasopharyngeal swab tests from this week. The test will be marketed under the brand name ''CIPtest''.

Reacting to the development, ON Wednesday shares of Cipla were trading Rs.4.10 higher at Rs. 785.75  per share NSE, during the mid-noon session.

H&M sales drop 10pc in Q4 on virus resurgence

Maharashtra govt reduces COVID RT-PCR test rates for around Rs 280

Corona vaccine will be applied first in Madhya Pradesh